Overall operational sales for Q1 grew 0.5% for Abbott Laboratories (ABT) to ~$5.2B. Diagnostics and Medical Devices grew 5.1% and 0.3%, respectively, while Nutrition fell 1.7% and Pharmaceuticals fell 0.7%.
International operations continue to deliver higher growth rates than domestic ops.
Ex-U.S. business delivered ~72% of global sales.
In the Nutrition segment, Adult International grew 12.4% versus growth in the U.S. of 5.2%. Pediatric fell in both markets.
Diagnostics grew in all segments and markets led by Molecular's 12.6% and POC's 10% increase internationally.
Pharmaceutical sales in key emerging markets (led by BRIC) were almost flat with a slight 0.2% gain.
International Device sales grew 4.7%.
Management confirms its 2014 EPS guidance range of $2.16 - $2.26 ex items.
GAAP EPS range for the fiscal year is $1.13 - $1.23.